Hospital

In a recent study, machine learning demonstrated its ability to predict progression to end-stage renal disease among patients with chronic kidney disease (CKD).

GLP-1 receptor agonists enhance glycemic control and weight management in youth with type 2 diabetes (T2D) and obesity, while safety concerns persist.

World Lymphoma Day highlights the rising prevalence of lymphoma and innovative treatments, emphasizing the role of pharmacists in patient care.

Research reveals that this population may experience lower short-term mortality rates after major surgery, challenging traditional BMI guidelines.

New FDA regulations are intended to enhance transparency in prescription drug advertising, empowering pharmacists to educate patients on medication risks and benefits.

Research reveals semaglutide's potential to reduce cocaine-seeking behavior in rats, suggesting a promising avenue for treating cocaine dependency in humans.

A panel of 4 experts discussed the most favored nation (MFN) initiative and its impacts on research and development, market and payer distributions, and pharmacists and patients.

The findings were presented at the 2025 American Heart Association Hypertension Scientific Sessions and published in the Journal of the American Society of Nephrology.

Researchers uncover a brain circuit linking stress to increased blood glucose, revealing insights into stress's role in type 2 diabetes (T2D) development.

GLSI-100 shows promise in preventing HER2-positive breast cancer recurrence after standard therapy.

A pharmacist-led initiative enhanced parenteral nutrition practices, improving patient outcomes and workflow efficiency while reducing errors and costs.

The FDA approves a groundbreaking gemcitabine system, offering new hope for patients with BCG-unresponsive bladder cancer.

Investigators emphasize that early cardiovascular risk assessments and preventive strategies are necessary for women with polycystic ovarian syndrome (PCOS).

The 2 abstracts, which were presented at the European Society of Cardiology 2025 Congress, utilized data from the CDC WONDER database.

RSV vaccination shows promise in reducing cardiorespiratory hospitalizations among older adults, highlighting potential heart and lung health benefits.

New research uncovers how smoking accelerates pancreatic cancer progression through immune mechanisms, revealing potential for targeted therapies and improved screening.

The FDA designates olomorasib as a breakthrough therapy, enhancing treatment options for advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutations.

September highlights Blood Cancer Awareness Month, focusing on education, early diagnosis, and support for multiple myeloma, lymphoma, and leukemia patients.

Individuals with learning disabilities face a heightened risk of severe type 2 diabetes (T2D), leading to increased mortality despite better glycemic control.

GLP-1 medications like semaglutide and tirzepatide significantly lower heart failure hospitalization risks, expanding treatment options for obesity-related conditions.

Pharmaceutical companies must consider formulation, packaging, and labeling from the start to minimize errors and protect patients.

Reduced-dose apixaban maintains efficacy with less bleeding for extended CAT prophylaxis, reinforcing NCCN’s preexisting guidance in intermediate to high-risk cancer patients.

New research reveals that women on beta-blockers post-heart attack face a 45% higher risk of serious health issues compared with men.

Women using depot medroxyprogesterone acetate face a significantly higher risk of meningioma, especially with long-term use or starting after age 31.

Compared with rivaroxaban, abelacimab significantly lowered bleeding risk in patients with atrial fibrillation regardless of kidney function.

A new oral PCSK9 inhibitor, enlicitide, shows promise in significantly lowering LDL cholesterol, offering hope for hypercholesterolemia management and cardiovascular health.

Moderate-to-severe TBI significantly increases the risk of malignant brain tumors, highlighting the need for long-term monitoring in survivors.

Abemaciclib significantly enhances overall survival in high-risk HR+, HER2- early breast cancer, establishing a new standard of care.

Subcutaneous bortezomib shows fewer adverse effects in multiple myeloma treatment compared with intravenous administration, enhancing patient outcomes.

Vaccination is vital for adults with heart disease to prevent severe respiratory illnesses like RSV, influenza, and COVID-19, enhancing overall health outcomes.